Solanezumab: Additional Phase III data

Researchers at the University of California, San Francisco, and colleagues reported data from an independent analysis of pooled data from the 18-month, double-blind, international Phase III EXPEDITION1 and EXPEDITION2 trials in 2,052 patients with mild to moderate AD showing that IV solanezumab non-significantly reduced blood levels of beta amyloid in patients with mild AD. The researchers said that the biomarker results suggest that solanezumab's cognitive benefit may be related to the removal of soluble amyloid from the brain into the blood. However, the researchers noted that solanezumab produced no changes in other AD biomarkers, including tau, phosphorylated tau, hippocampal volume, whole brain volume or amyloid accumulation as measured by PET imaging. Patients in the EXPEDITION trials received 400 mg IV solanezumab every 4 weeks. The Alzheimer's Disease Cooperative Study consortium presented the data at the Clinical Trials on Alzheimer's Disease meeting in Monte Carlo. ...